Art

J-GLOBAL ID：202002252141297192   Reference number：20A0593511

A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer

HER2陽性原発性乳癌におけるドセタキセル+カルボプラチン+トラスツズマブ+ペルツzumab(TCBHP),TCBHP,およびt-DM1+Pを比較した無作為化,3-腕,ネオアジュバント,第2相試験【JST・京大機械翻訳】

Author (19)： Masuda Norikazu (Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan) ,  Ohtani Shoichiro (Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan) ,  Takano Toshimi (Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan) ,  Inoue Kenichi (Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan) ,  Suzuki Eiji (Department of Breast Surgery, Kyoto University Hospital, Kyoto, Japan) ,  Nakamura Rikiya (Division of Breast Surgery, Chiba Cancer Center, Chiba, Japan) ,  Bando Hiroko (Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan) ,  Ito Yoshinori (Breast Medical Oncology Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan) ,  Ishida Kazushige (Department of Surgery, Iwate Medical University, Morioka, Japan) ,  Yamanaka Takashi (Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan) ,  Kuroi Katsumasa (Department of Breast Surgery, Tokyo Metropolitan Health and Hospitals Corporation Ebara Hospital, Tokyo, Japan) ,  Yasojima Hiroyuki (Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan) ,  Kasai Hiroi (Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan) ,  Takasuka Tsuyoshi (Oncology Lifecycle Management Department, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) ,  Sakurai Takaki (Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan) ,  Kataoka Tatsuki R. (Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan) ,  Morita Satoshi (Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan) ,  Ohno Shinji (Breast Oncology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan) ,  Toi Masakazu (Breast Cancer Unit, Kyoto University Hospital, Kyoto University, Kyoto, Japan)
Material： Breast Cancer Research and Treatment
Volume： 180  Issue： 1  Page： 135-146  Publication year： 2020 
JST Material Number： W4122A  ISSN： 1573-7217  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Abstract/Point： Abstract: Purpose: The standa...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A0593511&from=J-GLOBAL&jstjournalNo=W4122A") }}

Thesaurus term： *breast tumor ,  *carboplatin ,  EGF receptor ,  human(primates) ,  tumor ,  4 stroke cycle ,  molecular target therapy ,  *adjuvant ,  effectiveness ,  *phase 2 study ,  estrogen receptor ,  tricyclic diterpene
Semi thesaurus term： トラスツズマブエムタンシン ,  ペルツズマブ ,  *トラスツズマブ , 【Automatic Indexing@JST】

Author keywords (6)： Dual HER2-targeted therapy ,  Neoadjuvant therapy ,  Pertuzumab ,  Trastuzumab emtansine ,  Pathological complete response ,  Safety

JST classification (2)： Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L)

Substance index (1)： Taxane

Terms in the title (8)： HER2 ,  原発性乳癌 ,  ドセタキセル ,  カルボプラチン ,  トラスツズマブ ,  腕 ,  アジュバント ,  第2相試験